Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining patient risks from expanded preventive therapies.

K G Tolman1

  • 1Gastroenterology/Liver Division, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA.

The American Journal of Cardiology
|June 20, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thiazolidinedione hepatotoxicity: a class effect?

International journal of clinical practice. Supplement·2002
Same author

Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease.

Expert opinion on pharmacotherapy·2001
Same author

Eicosanoids and the liver.

Prostaglandins & other lipid mediators·2000
Same author

Hepatotoxicity of non-narcotic analgesics.

The American journal of medicine·1998
Same author

The effects of oral doses of lansoprazole and omeprazole on gastric pH.

Journal of clinical gastroenterology·1997
Same author

Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.

Epilepsia·1996
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Mild liver enzyme elevations are common with lipid-lowering drugs and usually transient, not predicting serious liver damage. Hepatotoxicity is a rare side effect, and routine monitoring may not be necessary for most patients.

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Trials

Background:

  • Lipid-lowering agents, including HMG-CoA reductase inhibitors, are associated with mild, asymptomatic elevations in liver enzymes like ALT.
  • The FDA recommended liver enzyme monitoring for most lipid-lowering drugs due to potential hepatotoxicity observed in animal studies.
  • Confounding factors such as alcohol, acetaminophen, and pre-existing liver conditions can also cause similar enzyme elevations.

Purpose of the Study:

  • To evaluate the clinical significance of alanine aminotransferase (ALT) elevations associated with lipid-lowering agents.
  • To determine if routine liver enzyme monitoring is necessary for patients taking lipid-lowering medications.
  • To differentiate between pharmacodynamic effects of lipid lowering and direct drug-induced hepatotoxicity.

Main Methods:

Related Experiment Videos

  • Review of clinical trial data for lipid-lowering agents, focusing on liver enzyme elevations (ALT).
  • Analysis of reported cases of hepatotoxicity linked to lipid-lowering drugs.
  • Assessment of the relationship between ALT elevations and actual hepatotoxicity.
  • Consideration of confounding factors influencing liver enzyme levels.

Main Results:

  • ALT elevations above the upper limit of normal occur in less than 3% of patients and are typically transient, dose-related, and resolve with continued therapy.
  • These mild ALT elevations have not been associated with hepatotoxicity.
  • Hepatotoxicity is a rare, idiosyncratic reaction reported with most lipid-lowering agents, except cholestyramine, with very few cases of liver failure linked to specific drugs like lovastatin.
  • There is no evidence that monitoring liver enzymes reduces the rate of hepatotoxicity.

Conclusions:

  • Mild, asymptomatic elevations in ALT are a class effect of lipid-lowering agents, likely related to lipid lowering rather than direct toxicity.
  • Routine monitoring of liver enzymes does not appear to reduce the incidence of rare hepatotoxic events.
  • Hepatotoxicity is an infrequent, idiosyncratic reaction, and current evidence does not support routine monitoring for all patients on these medications.